StockTipsArenaBeta

BUY GlaxoSmithKline Pharmaceuticals Limited — Bernstein

BUYGlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals share price target & all analyst calls

byBernsteinHorizon: NA (inferred 1 year)5 Nov 2026via NDTV Profit (Live)

Entry₹2,549.8Inferred
Target₹3,430
Total upside +34.52%
Stop lossNot given
CMP₹2,524.81d ago
Active-0.98%+35.85%upside left 12 mo left
Follow Bernstein for new callsGet alertsWatch GLAXO for new buy/sell callsGet alertsSee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:22 pm IST
11 supporting2 neutral0 opposing
Supports the BUY call (11)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

GlaxoSmithKline Pharmaceuticals reported Q2 FY2027 financial results with revenue of INR 1180 crore, a 21% YoY growth, and a 31% increase in Profit After Tax to INR 335 crore.

BSE · Company Update·3 Nov · 3d ago

(opens in new tab)

GlaxoSmithKline Pharmaceuticals reported standalone quarterly revenue of Rs 1,179.91 crore and profit of Rs 334.62 crore for the quarter ended September 30, 2026.

BSE · Company Update·3 Nov · 3d ago

(opens in new tab)

GlaxoSmithKline Pharmaceuticals reported standalone quarterly revenue of Rs 1,179.91 crore and profit of Rs 334.62 crore for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·3 Nov · 3d ago

(opens in new tab)

GlaxoSmithKline Pharmaceuticals reported standalone quarterly profit of Rs 334.62 crore for the quarter ended September 30, 2026, compared to Rs 255.00 crore in the same quarter last year.

BSE · Board Meeting·3 Nov · 3d ago

(opens in new tab)
Neutral / worth noting (2)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on GlaxoSmithKline Pharmaceuticals

All analyst calls on GlaxoSmithKline Pharmaceuticals

More from Bernstein

Every call and its outcome